6.07 USD
+0.23 (+3.94%)
Last: Feb 4, 2026, 04:30 PM
ICCC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. ICCC has only an average score on both its financial health and profitability. ICCC has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
- ICCC had positive earnings in the past year.
- ICCC had a positive operating cash flow in the past year.
- In the past 5 years ICCC always reported negative net income.
- The reported operating cash flow has been mixed in the past 5 years: ICCC reported negative operating cash flow in multiple years.
1.2 Ratios
- With an excellent Return On Assets value of 5.08%, ICCC belongs to the best of the industry, outperforming 91.60% of the companies in the same industry.
- ICCC has a Return On Equity of 7.80%. This is amongst the best in the industry. ICCC outperforms 91.79% of its industry peers.
- ICCC has a Return On Invested Capital of 4.41%. This is amongst the best in the industry. ICCC outperforms 91.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| ROIC | 4.41% |
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 8.37%, ICCC belongs to the top of the industry, outperforming 90.46% of the companies in the same industry.
- Looking at the Operating Margin, with a value of 8.39%, ICCC belongs to the top of the industry, outperforming 90.84% of the companies in the same industry.
- With a decent Gross Margin value of 40.93%, ICCC is doing good in the industry, outperforming 73.86% of the companies in the same industry.
- ICCC's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.39% | ||
| PM (TTM) | 8.37% | ||
| GM | 40.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICCC is destroying value.
- ICCC has more shares outstanding than it did 1 year ago.
- ICCC has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, ICCC has an improved debt to assets ratio.
2.2 Solvency
- ICCC has an Altman-Z score of 2.72. This is not the best score and indicates that ICCC is in the grey zone with still only limited risk for bankruptcy at the moment.
- ICCC has a better Altman-Z score (2.72) than 68.32% of its industry peers.
- The Debt to FCF ratio of ICCC is 13.27, which is on the high side as it means it would take ICCC, 13.27 years of fcf income to pay off all of its debts.
- Looking at the Debt to FCF ratio, with a value of 13.27, ICCC belongs to the top of the industry, outperforming 90.46% of the companies in the same industry.
- A Debt/Equity ratio of 0.27 indicates that ICCC is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.27, ICCC is doing worse than 67.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 13.27 | ||
| Altman-Z | 2.72 |
ROIC/WACC0.52
WACC8.48%
2.3 Liquidity
- A Current Ratio of 4.21 indicates that ICCC has no problem at all paying its short term obligations.
- With a Current ratio value of 4.21, ICCC perfoms like the industry average, outperforming 50.57% of the companies in the same industry.
- ICCC has a Quick Ratio of 1.76. This is a normal value and indicates that ICCC is financially healthy and should not expect problems in meeting its short term obligations.
- ICCC's Quick ratio of 1.76 is on the low side compared to the rest of the industry. ICCC is outperformed by 76.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.21 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
- ICCC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.00%, which is quite impressive.
- The Revenue has grown by 16.49% in the past year. This is quite good.
- The Revenue has been growing by 14.07% on average over the past years. This is quite good.
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 23.35, ICCC is valued on the expensive side.
- Based on the Price/Earnings ratio, ICCC is valued cheaply inside the industry as 94.47% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of ICCC to the average of the S&P500 Index (28.18), we can say ICCC is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.35 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ICCC is valued cheaply inside the industry as 96.37% of the companies are valued more expensively.
- ICCC's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ICCC is cheaper than 92.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 76.79 | ||
| EV/EBITDA | 11.63 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- ICCC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:ICCC (2/4/2026, 4:30:05 PM)
6.07
+0.23 (+3.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)02-25 2026-02-25
Inst Owners19.91%
Inst Owner Change1.61%
Ins Owners26.57%
Ins Owner Change0.51%
Market Cap54.93M
Revenue(TTM)27.77M
Net Income(TTM)2.32M
Analysts82.86
Price TargetN/A
Short Float %0.18%
Short Ratio0.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.35 | ||
| Fwd PE | N/A | ||
| P/S | 1.98 | ||
| P/FCF | 76.79 | ||
| P/OCF | 27.61 | ||
| P/B | 1.84 | ||
| P/tB | 1.85 | ||
| EV/EBITDA | 11.63 |
EPS(TTM)0.26
EY4.28%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY1.3%
OCF(TTM)0.22
OCFY3.62%
SpS3.07
BVpS3.29
TBVpS3.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number4.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.08% | ||
| ROE | 7.8% | ||
| ROCE | 5.58% | ||
| ROIC | 4.41% | ||
| ROICexc | 4.86% | ||
| ROICexgc | 4.87% | ||
| OM | 8.39% | ||
| PM (TTM) | 8.37% | ||
| GM | 40.93% | ||
| FCFM | 2.58% |
ROA(3y)-7.84%
ROA(5y)-5.24%
ROE(3y)-13.05%
ROE(5y)-8.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.67%
GM growth 5Y-9.41%
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 13.27 | ||
| Debt/EBITDA | 1.57 | ||
| Cap/Depr | 47.25% | ||
| Cap/Sales | 4.59% | ||
| Interest Coverage | 5.01 | ||
| Cash Conversion | 39.59% | ||
| Profit Quality | 30.79% | ||
| Current Ratio | 4.21 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z | 2.72 |
F-Score7
WACC8.48%
ROIC/WACC0.52
Cap/Depr(3y)82.27%
Cap/Depr(5y)105.22%
Cap/Sales(3y)11.34%
Cap/Sales(5y)14.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.49%
Revenue growth 3Y11.25%
Revenue growth 5Y14.07%
Sales Q2Q%-8.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y171.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y108.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y137.97%
OCF growth 3Y-27.78%
OCF growth 5Y9.25%
IMMUCELL CORP / ICCC FAQ
Can you provide the ChartMill fundamental rating for IMMUCELL CORP?
ChartMill assigns a fundamental rating of 4 / 10 to ICCC.
What is the valuation status of IMMUCELL CORP (ICCC) stock?
ChartMill assigns a valuation rating of 4 / 10 to IMMUCELL CORP (ICCC). This can be considered as Fairly Valued.
Can you provide the profitability details for IMMUCELL CORP?
IMMUCELL CORP (ICCC) has a profitability rating of 5 / 10.